Zhejiang Conba Pharmaceutical (600572.SH): New Drug Abbreviated Application for Entecavir Tablets Approved by FDA

Zhejiang Conba Pharmaceutical (600572.SH) announced that its wholly-owned subsidiary Zhejiang Jinhua Zhejiang Conba Pharmaceutical Biopharmaceutical Co., Ltd. (referred to as "Jinhua Zhejiang Conba Pharmaceutical") has received a notification from the U.S. Food and Drug Administration (FDA) that its wholly-owned subsidiary Conba USA Inc. (referred to as "USA Zhejiang Conba Pharmaceutical"), established in the United States, has obtained approval for its abbreviated new drug application (ANDA) for entecavir tablets filed with the FDA.